Platelets and coagulation factors are involved in the process of haemostasis, which ensures undisturbed blood flow upon vessel wall damage. However, excessive platelet aggregation and/or coagulation may lead to arterial or venous thrombosis. Pro-atherogenic lipoproteins, including native and oxidized low-density lipoprotein (LDL), are associated with an increased susceptibility to thrombosis. In contrast, numerous epidemiological studies have established an inverse correlation between high-density lipoprotein (HDL) levels and the risk for thrombosis. In addition to its role in reverse cholesterol transport, HDL also interacts with platelets, the coagulation cascade, and the vascular endothelium. Native HDL prevents platelet hyperreactivity by limiting intraplatelet cholesterol overload, as well as by modulating platelet signalling pathways after binding platelet HDL receptors such as scavenger receptor class B type I (SR-BI) and apoER2
Introduction
Low levels of circulating high-density lipoprotein (HDL) particles are generally associated with a higher incidence of atherosclerotic cardiovascular disease. 1 -4 Much of the atheroprotective effect of HDL is ascribed to its role in reverse cholesterol transport, removing excess cholesterol from peripheral tissues and delivering it to the liver for biliary secretion. 5 -7 However, HDL is more and more recognized as a multipurpose player in cardiovascular health and disease, exhibiting anti-inflammatory, antioxidative, immunomodulatory, anti-apoptotic, and antithrombotic effects. 8 For example, HDL has been shown to be an independent predictor of platelet-dependent thrombus formation. 9 The antithrombotic actions of HDL, which include the modulation of platelet reactivity, coagulation, and endothelial function, will be addressed in this review, summarizing recent findings from in vitro and in vivo animal studies, as well as from observational and interventional studies in humans.
HDL heterogeneity
Human HDL (1.063 -1.21 g/mL) is heterogeneous in terms of its density, size, shape, surface charge, and composition ( Table 1) . 10 Based on their size and density, HDL particles can be classified into two major subclasses: (i) small, dense (1.125-1.21 g/mL) HDL 3 and (ii) larger, less dense (1.063 -1.125 g/mL) HDL 2 . 11 When separated by gradient gel electrophoresis, further subspecies can be identified: HDL 2b (largest) . HDL 2a . HDL 3a . HDL 3b . HDL 3c . Distinct HDL subpopulations have also been identified on the basis of their apolipoprotein composition. Some particles contain only apolipoprotein A-I (apoA-I), whereas others contain both apoA-I and apoA-II, or apoA-I and apoE. In general, HDL 2 particles are apoE-and apoA-I-rich, whereas HDL 3 particles are apoE-poor and apoA-I-and apoA-II-rich. It has been suggested that apoA-I-containing HDL may be more cardioprotective than apoA-I/-II-containing HDL, 12 and that HDL 2 might be superior to HDL 3 in this respect. 13 A high level of heterogeneity is also found in the lipid content across HDL subpopulations. HDL consists predominantly of phospholipids and sphingomyelin (40-60% of total weight), while cholesteryl esters (30-40%), triglycerides (5-12%), and unesterified cholesterol (UC; 5-10%) make up the rest of the particle. A recent structure-function analysis revealed that several phospholipid classes, and primarily negatively charged phosphatidylserine and phosphatidic acid, are enriched in HDL 3 , which was positively associated with its cholesterol efflux capacity, as well as its antioxidative, anti-inflammatory, anti-apoptotic, and antithrombotic activities. 8 Antithrombotic activity of HDL subfractions was evaluated as their ability to inhibit H 2 O 2 -induced platelet activation, by measuring phosphorylation of p38 mitogenactivated protein kinase (p38 MAPK ) and the production of thromboxane B 2 (TxB 2 ), the inactivate metabolite of TxA 2 , which is produced by activated platelets. Small, dense HDL 3 was superior over larger and less dense HDL 2 in the prevention of H 2 O 2 -induced p38 MAPK phosphorylation and TxB 2 production. These differences potentially reflect the distinct proteome and lipidome of HDL 3 compared with HDL 2 , as HDL 3 is enriched in bioactive lipids and proteins. The exact contribution of the different constituents of HDL on its antithrombotic activity will be discussed throughout this review.
Aetiology of thrombosis
Undisturbed blood flow upon vessel wall damage is ensured by the process of haemostasis that involves platelets and coagulation factors. However, excessive platelet aggregation or coagulation may lead to two different forms of thrombosis, i.e. arterial and venous thrombosis, respectively. Arterial 'white' thrombi develop in areas of high shear stress, are platelet-rich, and manifest as myocardial infarction, unstable angina, ischaemic stroke, or peripheral artery disease. In contrast, venous 'red' thrombi usually develop in low flow vessels, are red cellrich, and their formation is highly dependent on hypercoagulability and venous stasis. Increasing evidence suggests an association between arterial and venous thrombosis. 14 Prandoni et al. 15 were the first to demonstrate a higher prevalence of asymptomatic atherosclerosis in patients with previous idiopathic venous thromboembolism (VTE), also after adjustment for risk factors of atherosclerosis. Later studies also observed an increased incidence of atherosclerotic cardiovascular events in VTE patients. 16 -21 However, other studies found no such correlation. 22, 23 Correspondingly, two large cohort studies found that hypertension, dyslipidaemia, diabetes mellitus, smoking, and physical activity were significantly associated with the risk of myocardial infarction due to arterial thrombosis, but not with VTE. 24, 25 Therefore, it was suggested that the link between venous and arterial thrombosis may be largely explained by mechanisms of thrombus formation and hypercoagulability rather than the development of atherosclerosis. 24 For example, recent evidence suggests that procoagulant microparticles and neutrophil extracellular traps might be prothrombotic mechanisms shared by both arterial and venous thrombosis. 26 2. HDL and the incidence of arterial thrombosis
Platelets and the development of arterial thrombosis
The primary role of platelets is to seal the damaged vessel wall upon injury and to stimulate repair of the endothelium by the release of cytokines, chemokines, and growth factors. 27 Upon endothelial damage, von Willebrand factor (vWF), released into the circulation from endothelial WeibelPalade bodies, adheres to collagen in the subendothelium exposed to the flowing blood in the injured area. Platelets can bind to the immobilized vWF via the glycoprotein Ib-V-IX (GPIb-V-IX) complex on the platelet membrane. However, the interaction of vWF with GPIb-V-IX is transient and does not allow stable adhesion, but it initiates the tethering of platelets over the endothelium and induces a weak intracellular signalling pathway. This allows subsequent interaction of additional receptors such as integrin a IIb b 3 , a 2 b 1 , and GPVI with vWF and collagen, respectively, resulting in firm adhesion. The activated platelets release its alpha and dense granule contents, and synthesize and release platelet-activating TxA 2 . Further stabilization is ensured by platelet spreading, which is primarily mediated by integrin a IIb b 3 . The spread platelet provides a new surface for the next platelet to adhere to via fibrinogen that is bound by integrin a IIb b 3 of two adjacent platelets, thereby inducing platelet aggregation ( Figure 1 ). Platelets are also involved in the development of acute coronary syndromes and cerebrovascular diseases. 28 Based on their size and density, HDL particles can be classified into six classes, which differ in lipid and apolipoprotein content. shown that low levels of HDL-cholesterol (HDL-C) are an important risk factor for coronary artery disease (CAD). 35 The Atherosclerosis Risk in Communities (ARIC) study found lower HDL-C levels in men (1.07 vs. 1.18 mmol/L) and women (1.30 vs. 1.51 mmol/L) with CAD. 36 Similarly, the Emerging Risk Factors Collaboration, involving 68 prospective studies of cardiovascular risk factors, found 6.4 cases of CAD per 1000 subjects in the lowest tertile (0-33%) of plasma HDL-C levels, whereas the incidence was much lower (2.4 per 1000) in the highest tertile. 37 In the LUdwigshafen RIsk and Cardiovascular health (LURIC) study, HDL-C was strongly associated with cardiovascular death in people without CAD, but not in patients with stable and unstable CAD, indicating that the inverse relationship of HDL-C with cardiovascular death is weakened in these patients. 38 Even in patients treated with intense statin therapy and having target levels of LDL-C, HDL-C remains a predictor of outcome for major adverse cardiovascular events. 39 Limiting the build-up of cholesterol in atherosclerotic plaques is an important atheroprotective function of HDL, but the platelet-modulatory actions of HDL, summarized in Figure 2 , also play a central role.
HDL and platelet formation and clearance
Lipoproteins can influence platelet count and characteristics, and modulate the risk of atherothrombosis via the megakaryocyte -platelet haemostatic axis. 40 Dyslipidaemia leads to altered characteristics of megakaryocytes, precursor cells residing in the bone marrow responsible for platelet production. This is illustrated by the observation that megakaryocytes from hypercholesterolaemic rabbits, guinea pigs, and humans are significantly larger and have a higher mean ploidy than those from matched control subjects. 41 -43 High-ploidy megakaryocytes are generally considered to produce larger and more active platelets, as observed in experimentally induced thrombocytopenia. 44 Not only high plasma lipid levels, but also processes implicated in the export of lipids from megakaryocytes, influence the characteristics of megakaryocytes. In line with this, Murphy et al. 45 observed increased megakaryocyte proliferation and platelet production in LDL receptordeficient (LDLr 2/2 ) mice with bone marrow-specific ATP-binding cassette transporter G4 (ABCG4) deficiency, which display defective cholesterol efflux from megakaryocytes to HDL. Conversely, infusions with reconstituted HDL (rHDL) significantly reduced platelet counts in LDLr 2/2 mice, but not in LDLr 2/2 /ABCG4 2/2 mice, indicating an essential role for ABCG4 in mediating the ability of rHDL to reduce megakaryocyte proliferation and platelet production. The effect of modulation of HDL metabolism on platelet count and morphology was also studied in mice that are deficient for the HDL receptor scavenger receptor class B type I (SR-BI 2/2 ). SR-BI 2/2 mice have an unusually high plasma unesterified-to-total cholesterol (UC : TC) ratio, and the cholesterol is carried by abnormally large HDL particles, reflecting impaired delivery of cholesterol to the liver. SR-BI deficiency was shown to cause thrombocytopenia, while the circulating platelets The interaction of GPVI with collagen leads to further platelet activation. (4) Activated platelets will spread and form a surface to which other platelets can bind. (5) Upon activation, platelets release their alpha and dense granule contents (e.g. ADP), and synthesize and release platelet-activating TxA 2 . Integrin a IIb b 3 in its active conformation on activated platelets binds fibrinogen, which forms a bridge between two activated platelets.
displayed abnormal cell morphology and were abnormally large due to an increased UC content. 46, 47 A high-fat/high-cholesterol diet further enhanced the effects of SR-BI deficiency on platelet count and morphology. Increased platelet clearance is believed to be the driving force behind the observed thrombocytopenia, since the rate of platelet production was unaffected. The increased UC content and reduced lifespan of these platelets appeared to be primarily dependent on the external environment, and not to be an intrinsic feature of these platelets, as wildtype platelets adopted the same characteristics as resident platelets when infused into SR-BI 2/2 mice. Furthermore, the UC content and clearance rate of SR-BI 2/2 platelets was at least partially normalized after infusion into wild-type mice. Noteworthy, hypomorphic liverspecific SR-BI L2/L2 mice with similarly elevated HDL-C levels as total body SR-BI 2/2 mice also displayed a dramatic reduction in circulating platelet count. 48 In contrast, platelet-specific deletion of SR-BI by specifically disrupting SR-BI in bone marrow-derived cells from wild-type mice by a bone marrow transplantation approach did not affect platelet count, size, or UC content. 47 Platelet characteristics were also studied in SR-BI 2/2 mice expressing cholesteryl ester transfer protein (CETP), which normalized HDL-C levels. 48, 49 In these mice, the plasma UC :
TC ratio was partially restored but remained elevated. Probably as a result of this, SR-BI 2/2 /CETP mice still displayed thrombocytopenia.
The functional consequence of SR-BI dysfunction in humans has been studied in people carrying a heterozygous SR-BI variant, P297S. 50 The mutation carriers had increased HDL-C levels (1.8 vs. 1.4 mmol/L), but their plasma UC : TC ratio was unchanged. Mean platelet counts did not differ significantly between P297S carriers and non-carriers, but platelets from carriers were UC-rich, as observed in SR-BI 2/2 mice.
Impact of high HDL-C due to SR-BI deficiency on platelet reactivity and thrombosis
We, and others, also studied the effect of SR-BI deficiency on platelet function and thrombosis susceptibility. 46 ′ and SR-BI on the platelet membrane induces signalling pathways that suppress platelet activation (e.g. surface P-selectin expression and integrin a IIb b 3 activation). In contrast, heavily oxidized HDL binds platelets via CD36, thereby inducing platelet activation. Accumulation of UC is prevented by uptake of excess platelet cholesterol by HDL via SR-BI. This is illustrated by the abnormally large platelets from SR-BI 2/2 mice that are rich in UC, and circulate in a hyperreactive state.
a
After identification of SR-BI on megakaryocytes and platelets, 57 Brodde et al. 58 identified SR-BI as the primary binding site for HDL 3 on platelets. Binding of HDL 3 was significantly inhibited by liposomes containing anionic phospholipids and by lipid-free maleylated BSA, known ligands for SR-BI. 59, 60 Similar to HDL, these ligands attenuated platelet activation, including thrombin-induced intracellular calcium mobilization, fibrinogen binding, surface expression of P-selectin, and aggregation. These inhibitory effects were mediated via decreased generation of diacylglycerol and activation of protein kinase C. 61 Importantly, SR-BI 2/2 platelets were not affected by HDL 3 or other SR-BI ligands, which further pointed to SR-BI as a functional receptor for HDL attenuating agonist-induced platelet activation. In addition, platelets express CD36, another member of the class B scavenger receptor superfamily that binds HDL. 62 However, deficiency of platelet CD36 did not affect the inhibitory effect of HDL 3 on platelet reactivity. Compared with native HDL, CuSO − 4 or myeloperoxidase-oxidized HDL (oxHDL) is a more potent inhibitor of agonist-induced platelet activation, and this effect is also mediated by SR-BI. 63 Calzada et al. studied platelet function in patients with abetalipoproteinaemia (ABLP) lacking apoB-containing lipoproteins in plasma. These patients primarily transport cholesterol via HDL, which is oxidized due to impaired protection against oxidative stress, as a result of extremely low plasma levels of the antioxidant vitamin E. 64 Platelets isolated from plasma of ABLP patients are hyperreactive to collagen, arachidonic acid, and thrombin compared with those isolated from control plasma upon resuspension in a buffer solution. However, in platelet-rich plasma, no differences in the extent of aggregation between control and ABLP platelets were observed, indicating that ABLP plasma contains a protective factor preventing the augmented platelet aggregation. Lipoprotein removal from ABLP plasma abolished this protective effect. Since oxHDL is the sole lipoprotein in ABLP plasma, it is most likely this oxidized HDL that is responsible for the inhibitory effect. Here too, SR-BI was identified as the receptor for oxHDL on platelets. The results from these studies are in seeming contrast to others that show that, upon (heavy) oxidation by hypochlorite, HDL enhances platelet aggregation. 65, 66 In these studies, oxHDL was found to bind to platelet CD36. Hence, the degree and type of HDL oxidation seem to determine the affinity for either SR-BI or CD36 and thereby its capacity to inhibit or stimulate agonist-induced platelet activation, respectively ( Figure 2 ).
67
In addition to SR-BI as a functional receptor for HDL, Owen and colleagues 68 reported another possible platelet receptor for apoEcontaining HDL. They identified a splice variant of the LDL receptor family member low-density lipoprotein receptor-related protein 8 (LRP8)/apoE receptor 2 (apoER2) (apoER2 ′ ), lacking binding repeats 4-6, both in megakaryocytic cell lines and in platelets. Binding of apoE-rich HDL 2 to apoER2 ′ was found to reduce adenosine diphosphate (ADP)-, epinephrine-, and collagen-induced platelet aggregation, whereas the apoE-poor fraction only had a minor inhibitory effect. 69 Similarly, phospholipid vesicles containing apoE suppressed platelet aggregation. 70 Platelet inhibition may be due to apoE-mediated stimulation of the release of nitric oxide (NO) from platelets, which acts on soluble guanylate cyclase to elevate levels of anti-aggregatory cGMP. Interestingly, apoER2 ′ also mediates signalling induced by LDL, which leads to enhanced platelet aggregation. 71 LDL binds platelet apoER2 ′ via the so-called B-site of apoB100. 72 Binding of LDL to platelets results in phosphorylation and activation of intracellular p38 MAPK . 73 Subsequently, this Ser/Thr kinase phosphorylates and activates cytosolic phospholipase A 2 , which leads to the formation of platelet-activating TxA 2 . 74, 75 HDL is also able to induce p38 MAPK activation, although the response is weaker than observed for LDL. 72 Residues 142-152 of apoE closely resemble the B-site of apoB100, and a peptide mimicking this domain also induces phosphorylation of p38
MAPK
. Hence, the platelet-activating property of apoE-containing HDL 2 probably lies within this part of apoE and may also be responsible for the platelet-activating effects of HDL observed in some studies. 76 
HDL and venous thrombosis
While the inverse relationship between plasma HDL-C levels and the risk of arterial thrombosis has been well described, the effect of HDL-C levels on the risk of venous thrombosis is less clear. Deguchi et al. 77 found significantly lower levels of (large) HDL 2 particles, HDL-C and apoA-I in patients with deep venous thrombosis (DVT) with or without pulmonary embolism. This was paralleled by significantly higher levels of LDL particles. In a later study of VTE cases, they calculated a relative risk of recurrence of 0.87 (95% CI 0.80 -0.94) for each increase of plasma apoA-I by 0.1 mg/mL. 78 Patients with VTE had a lower frequency of the TaqI B2 allele, a polymorphism which is associated with decreased CETP levels and activity, and thus higher HDL-C levels. 79 Correspondingly, in a meta-analysis of 21 casecontrol and cohort studies, Ageno et al. 80 observed significantly lower levels of HDL-C in VTE patients. However, others found no such correlation, 81 -83 or even an association of high HDL-C levels with an increased risk of VTE in women. 84, 85 These latter observations were likely the result of prothrombotic effects of hormone therapy, which concomitantly increases HDL-C levels. 86 
HDL as a modulator of the coagulation cascade
The conversion of the soluble plasma protein fibrinogen into insoluble fibrin fibres, mediated by thrombin (factor IIa, FIIa), is the central step of the coagulation cascade ( Figure 3) . The cascade starts with the exposure of blood to tissue factor (TF) via the extrinsic pathway, or with negatively charged surfaces via the intrinsic pathway. In the extrinsic pathway, after exposure to blood, TF binds to circulating active FVII (FVIIa). This complex, known as the extrinsic tenase complex, activates FX forming FXa. The intrinsic pathway starts with the activation of coagulation factor XII, which will lead to the activation of factor XI. Activated FXI (FXIa) will then activate factor IX, which forms a complex with FVIIIa. The resulting intrinsic tenase complex then converts FX to its active form. Both pathways culminate in the common pathway of coagulation, in which the prothrombinase complex (FXa and FVa) converts prothrombin into thrombin. HDL modulates the coagulation cascade at different levels (see Figure 3 for overview). For example, a positive correlation between plasma apoA-I levels and the in vitro anticoagulant response was found, as well as an inverse relation between HDL and prothrombin fragments F1 + 2, the peptide cleaved from prothrombin during its conversion to thrombin. 87 ApoA-I also neutralizes the procoagulant properties of anionic phospholipids. 88 Incorporation of apoA-I into anionic vesicles prevents the formation of the prothrombinase complex due to the inability of FVa to bind to the vesicles, while binding of prothrombin and FXa is unaffected. Similarly, addition of serum neutralizes the procoagulant effect of anionic liposomes, by mediating the transfer of phospholipids to either apoA-I-or apoB-containing lipoproteins. 89 Another way by which HDL exerts anticoagulant functions is via the protein C pathway. This pathway comprises the generation of the proteolytically active form of the vitamin K-dependent zymogen protein C (activated protein C, APC), which is able to inactivate FVa and FVIIIa. 90, 91 The anticoagulant activity of APC is enhanced by vitamin K-dependent protein S, which serves as a cofactor for APC. Purified HDL, but not LDL, enhances protein S-dependent cleavage of FVa at Arg 206 by APC. 92 Moreover, infusion of rHDL in an experimental rabbit model of atherosclerosis increased the expression of thrombomodulin in lesions, which is an additional coagulant factor that supports activation of protein C and suppresses thrombin generation. 93 
HDL is positively associated with fibrinolysis
Clot formation is counteracted by the process of fibrinolysis, inducing the degradation of a blood clot. The stability of a blood clot is determined by the rate of coagulation and fibrinolysis. Dense and poorly lysable clot formation is observed in cardiovascular disease. 94 During fibrinolysis, fibrin is cleaved by plasmin, which is formed from plasminogen by tissue-and urokinase-type plasminogen activator (tPA and uPA), both secreted by endothelial cells. Elevated HDL-C levels are associated with increased fibrin clot permeability and reduced clot lysis time. 95 Moreover, both HDL-C and HDL size are inversely related to the levels of PA inhibitor-I (PAI-I), an inhibitor of tPA and uPA, implying that HDL particles might help reduce the thrombotic risk by promoting plasmin generation and thus fibrinolysis. 96, 97 Correspondingly, both HDL-C and HDL size correlate with the levels of D-dimer, a fibrin degradation product. In contrast, oxHDL, which has been detected in atherosclerotic plaques, has been found to promote PAI-I expression in endothelial cells, implying that oxHDL reduces fibrinolysis and contributes to clot stability. 98 
HDL and the vascular endothelium
The vascular endothelium is very important in the regulation of platelet and coagulation responses. For example, endothelial cells produce NO, which is a potent platelet inhibitor. NO is generated by endothelial NO synthase (eNOS), in response to agonists of various cell surface receptors and physical stimuli such as shear stress. 99 NO acts by directly activating platelet guanylyl cyclase, resulting in an increase of intraplatelet cGMP, which represses platelet activation. 100 Pro-atherogenic lipids such as oxLDL inhibit eNOS activation by changing its subcellular localization. 101 This effect is counteracted by HDL, thereby retaining eNOS localization and NO production. 102 HDL is also able to directly stimulate eNOS in endothelial cells in a process that requires apoA-I binding to SR-BI. 103 In a murine flow restriction model in the inferior vena cava, infusion of apoA-I protected wild-type mice from DVT, but not SR-BI
or eNOS 2/2 mice. 104 As apoA-I did not affect platelet aggregation, this effect was platelet-independent. In addition to promoting NO production, HDL can also induce the synthesis of prostacyclin (PGI 2 ), which inhibits platelet aggregation by increasing intraplatelet cAMP. PGI 2 is synthesized from arachidonate in a pathway that involves cyclooxygenase (COX). 105 There are two isoforms of this enzyme: COX-1, which is constitutively expressed, and COX-2, which is inducible. Endothelial PGI 2 synthesis is stimulated by HDL, by the provision of arachidonic acid, and by inducing COX-2 expression. 106 -110 Moreover, in isolated rabbit and rat hearts, HDL was
shown to enhance the release of prostaglandins, which are precursors of PGI 2 synthesis. 111, 112 Little is known about the effect of HDL on PGI 2 synthesis in humans, except for the positive correlation of plasma HDL-C levels with the plasma concentration of the PGI 2 metabolite 6-keto PGF 1a . 113, 114 Upon vascular injury, platelets are recruited to the damaged vascular wall and under high shear stress, platelet adherence is mediated by vWF, a constituent of endothelial Weibel-Palade bodies. 115 In patients with peripheral vascular disease, levels of circulating vWF are inversely associated with HDL. 116 Further evidence for an effect of HDL on endothelial vWF secretion was found in a mouse model of DVT, where apoA-I inhibited platelet recruitment by the venous endothelium, presumably by suppressing the release from Weibel-Palade bodies. 104 The vascular endothelium not only modulates platelet reactivity, but also the coagulation response. For example, tissue factor pathway inhibitor (TFPI) is secreted by endothelial cells to inhibit the extrinsic pathway of coagulation. So far, the existence of epidemiological associations between circulating TFPI and HDL in humans is still unclear, as one study suggested a negative correlation, 117 whereas another showed a positive correlation. 118 The endothelium also modulates coagulation by expressing heparin-like proteoglycans on the endothelial cell surface, enabling the endothelium to bind and activate antithrombin III, which subsequently inhibits the coagulation cascade by suppressing various coagulation factors, mainly FIIa, FXa, and FIXa. The apoE moiety of HDL was shown to increase endothelial production of heparan sulfate rich in biologically active heparin-like domains, 119 leading to a significantly higher binding of antithrombin III to the matrix of endothelial cells pre-incubated with HDL compared with the matrix of non-treated control cells. In addition to its suppressive effects on primary and secondary haemostasis, HDL may also reduce thrombosis by inhibiting apoptosis of endothelial cells, which would otherwise turn the endothelium into a procoagulant surface. 120, 121 HDL suppresses the mitochondrial pathway of apoptosis by preserving mitochondrial integrity and inhibiting the release of cytochrome c into the cytoplasm. These anti-apoptotic effects are mediated by the protein kinase Akt, an ubiquitous transducer of anti-apoptotic signals. Since two isolated lysosphingolipids, sphingophosphorylcholine and lysosulfatide, also stimulate Akt and inhibit apoptosis, it is believed that these components of native HDL are responsible for the endothelium-protective effects of HDL. 122 
rHDL as the treatment for arterial and venous thrombosis
Therapeutic agents that raise HDL-C are currently being tested for the prevention and treatment of cardiovascular diseases. One promising strategy is the use of synthetic rHDL, containing phospholipids and human apoA-I or one of its variants, such as apoA-I Milano , which is functionally more effective. 123 Lerch et al. 124 tested the effects of rHDL on platelet reactivity, and found a dose-dependent inhibition of in vitro platelet aggregation by rHDL after stimulation with arachidonic acid, collagen, epinephrine, or ADP. Subsequently, they performed ex vivo experiments with platelet-rich plasma isolated from volunteers who had been infused with rHDL. Both arachidonic acid-and collagen-induced platelet aggregation were reduced, and the extent of inhibition negatively correlated with plasma concentration of apoA-I, HDL-C, and the dose of rHDL infused. Consistent with these findings, administration of recombinant apoA-I Milano inhibited platelet aggregation and FeCl 3 -induced arterial thrombus formation in rats. 125 These effects were platelet-dependent, as no effects on vasoconstriction or endothelium-dependent relaxation were observed. Calkin et al. 126 studied the benefit of rHDL therapy in patients with Type 2 diabetes mellitus, who have an increased risk of cardiovascular disease and exhibit enhanced platelet reactivity. rHDL infusion significantly reduced ex vivo platelet aggregation and thrombus formation under flow. These effects were mainly ascribed to the isolated phospholipid component of rHDL, and not to apoA-I. Moreover, rHDL enhanced efflux of cholesterol from platelets and interfered with lipid raft assembly in the platelet membrane, as did other unspecific cholesterol acceptors such as cyclodextrin or phosphatidylcholinecontaining vesicles, which also reduced the platelet response. In contrast, native HDL particles were much less effective in removing cholesterol and did not affect platelet aggregation, although it must be noted that sub-physiological concentrations were used. These observations suggest that rHDL affects platelets mainly by promoting cholesterol efflux and changing lipid raft organization, rather than by inducing platelet signalling via specific receptors on the platelet membrane. 76 rHDL has also been shown to reduce coagulation responses. For example, in LPS-induced endotoxaemia, rHDL reduces plasma levels of prothrombin fragment F1 + 2 and induces plasma levels of tPA. 127 Although the underlying mechanisms remain to be elucidated, rHDL infusions are a promising therapeutic strategy to reduce thrombosis risk, not only in patients with cardiovascular disease, but also under other conditions where platelet hyperreactivity and hypercoagulability pose a threat.
Conclusion
In addition to its role in reverse cholesterol transport, the vascular protective effects of HDL can at least be partially explained by its antithrombotic actions. Native HDL prevents platelet hyperreactivity by limiting intraplatelet cholesterol overload, as well as by modulating platelet signalling pathways. The antithrombotic properties of native HDL are also related to suppression of the coagulation cascade and stimulation of clot fibrinolysis. Furthermore, HDL stimulates the endothelial production of NO and PGI 2 , which are potent inhibitors of platelet activation. Raising HDL levels may therefore be an important therapeutic strategy to reduce the risk of arterial and venous thrombosis. However, not only the level of circulating HDL is an important determinant for its antithrombotic effects, but its composition is also an important determinant. The subclass, apolipoprotein and lipid composition, and the degree of oxidation determine to which receptor the HDL particle will bind, and thereby the capacity to inhibit or stimulate agonist-induced platelet activation. Hence, more detailed structure-function analyses are needed to identify clinically relevant, antithrombotic HDL subpopulations, in order to diagnose patients at risk and to develop effective therapeutic approaches to reduce thrombotic risk.
